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strategies T16/I3,I3 and I3/T12,T12 were dominated by
T16/I3,T12. The incremental analysis vs. strategy T12/
I3,T12 indicated, that T16/I3,T12 and I4/T12,T12 were
not cost-effective alternatives for T12/I3,T12 with ICER
14 743 and 19 687 PLN/mycological cure gained, respec-
tively. Changing the values of key drivers in the sensitiv-
ity analysis did not have any significant effect on ICER.
CONCLUSION: T12 as primary treatment with I3 as
treatment of failure and T12 as treatment of re-infection
was the most cost-effective treatment for toenail onycho-
mycosis in Poland.
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OBJECTIVE: Upper respiratory tract infections are fre-
quent in children. Their economic impact is widely un-
known. This study responded to a request from the
French Economic Committee to estimate the direct cost
of an acute rhino-pharyngitis (ARP), the effectiveness of
Imocur® (OM-85 BV indicated for the prevention of re-
currences), and the cost effectiveness of this strategy com-
pared to placebo from a Social Security perspective.
METHOD: Costs, probabilities of short-term complica-
tions, associated care, effectiveness of Imocur during the
winter period were based on review of the literature, na-
tional health statistics and consulting experts’ opinions.
An incremental cost-effectiveness model was used.
RESULTS: The mean direct cost for an ARP is €49.5.
Among children with recurrent infection, 1.52 infections
during the winter period is avoided using this type of pre-
vention and Social Security saves approximately €68 per
child on the cost of care. The sensitivity analyses confirm
the robustness of the model, and show that prevention
with Imocur allowed Social Security to save between 28
and 304 € in direct costs for each at-risk individual who
received preventive treatment. The threshold analysis
shows that this type of prophylaxis is economically prof-
itable for the community starting from 0,15 prevented in-
fections and direct costs of care of an acute infection
exceeding 4.77 €. The demonstration is valid with recur-
rently-infected children, a population for which the effec-
tiveness of Imocur has been established. If we had taken
into account other payers’ viewpoints and the indirect
costs, our conclusions would have been reinforced.
CONCLUSION: Non-specific immunotherapy is a rea-
sonable measure to be considered for prevention of recur-
rences and should be associated with recommended mea-
sures in children at risk. The French health authorities
considered the economic value of an effective medication
to the community in assessing its usefulness.
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OBJECTIVES: Morbidity due to respiratory infections
leads to significant adverse societal and economic conse-
quences. This study investigates the extent to which treat-
ment for respiratory infections imposes a financial burden
on an employer, and documents variations in employer
payments between specific respiratory infections.
METHODS: The data source is a rich administrative
claims database for a national, Fortune 100 manufac-
turer. It includes 1997 medical, pharmaceutical, and dis-
ability claims for employees, spouses, dependents, and re-
tirees (n  100,000) under age 65. The research sample
consists of individual patients with one or more medical
or disability claims for at least one of eleven infectious re-
spiratory conditions. Resource utilization is contrasted
with a 10 percent random sample of the employer’s over-
all beneficiary population.
RESULTS: Direct (medical and pharmaceutical) and in-
direct (disability and sporadic absenteeism) costs are an-
alyzed. The average per capita annual costs are: for the
entire employer population, $2,368; for all respiratory-
infection patients, $4,397, and for respiratory-infection
employees eligible for disability, $6,838. Total costs for
respiratory-infection patients are 1.8 times those for the
typical beneficiary. Total costs are highest for patients
with pneumonia ($11,544) and lowest for patients with
acute tonsillitis and acute pharyngitis ($2,180). Medical
and pharmaceutical treatments account for 65% of total
costs for all employees with respiratory infections, while
the remaining 35% of costs are attributable to disability
and sporadic absenteeism.
CONCLUSIONS: Respiratory infections impose a signif-
icant financial burden on the employer. Resource utiliza-
tion by respiratory infection patients is substantial, not
only for the direct treatment of respiratory infections, but
also for the treatment of co-morbid medical conditions of
these patients. These costs also vary considerably by type
of respiratory infection. The study also shows that respi-
ratory infections impose substantial indirect costs on em-
ployers from work loss associated with these infections.
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The incidence of multiple drug resistant tuberculosis
(MDR-TB) is increasing worldwide, limiting the effec-
tiveness of conventional drug therapies. Fluoroquinolone
antibiotics may offer an effective drug treatment option
for susceptible and MDR-TB.
OBJECTIVE: To review clinical and non-clinical evi-
dence of the efficacy, safety, and product characteristics
of fluoroquinolones with regard to their potential use in
the treatment of pulmonary TB.
METHODS: This review focused on fluoroquinolones
that have been approved for marketing in the US. Char-
acteristics assessed included: dosage; dosing frequency; ap-
proved indications; treatment duration; pharmacodynamics/
pharmacokinetics; adverse events; drug interactions; mu-
tagenic and teratogenic potential; structure-function relation-
ships; long-term use; Cmax and AUC ratios for M. tuberculo-
sis; and efficacy against susceptible and MDR-TB as reported
from in vitro, animal model, and clinical assessments. Infor-
mation was taken from the Physician’s Desk Reference, Drug
Facts and Figures, product monographs, medical literature in-
cluding clinical trial reports, the Food and Drug Adminis-
tration’s Center for Drug Evaluation and Research (CDER)
approval packages for fluoroquinolones, and expert opinion.
RESULTS: The earliest introduced fluoroquinolones,
such as norfloxacin and enoxacin, are least likely to be
useful in treating TB, due to low clinical efficacy. Trova-
floxacin is also ineffective against TB, and has undesir-
able adverse effects. Some fluoroquinolones, such as
sparfloxacin, offer efficacy against TB, but also have
problematic adverse effects. Ciprofloxacin and ofloxacin
are moderately effective against TB, and have generally
favorable characteristics. Levofloxacin has shown effi-
cacy in vitro and in animal models, as well as favorable
drug interaction and adverse event profiles, but human
efficacy is inconclusive. Moxifloxacin and gatifloxacin
may offer similar profiles to levofloxacin, but clinical
trial efficacy data is insufficient to draw conclusions.
CONCLUSIONS: While no one fluoroquinolone pos-
sesses all of the desirable characteristics for a new pulmo-
nary TB therapy, there are a number of candidates that
may have clinical efficacy and generally favorable profiles.
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In 1997, there were approximately eight million new ac-
tive cases of tuberculosis but only two percent of cases
were in established market economies. There is a need for
new drugs that could shorten treatment times but a con-
cern about return on investment (ROI) in this disease
area.
OBJECTIVE: To measure the ROI for a tuberculosis
drug development program.
METHODS: ROI may be measured by computing the net
present value of the estimated costs and revenue streams.
An EXCEL spreadsheet model was prepared that had a
25-year time horizon, starting as the molecule entered
Phase 1 trials. The model included costs for clinical trials,
non-clinical development, manufacturing development,
cost of goods, and sales and marketing. Revenues were
estimated for each year after launch assuming three years
to peak sales, five years at peak sales, and a 20 year
patent life from the start of Phase 1. A discount rate of 12
percent was used to compute the net present value. Alter-
native cost scenario models were based on whether time
from start of Phase 1 to launch was 10 years (normal) or
seven years (rapid) and whether clinical trials were con-
ducted in the US or Uganda. Alternative revenue scenar-
ios were also modeled.
RESULTS: Total discounted costs were $13.9 million,
$21.3 million, $9.0 million, and $13.7 million for the
normal US, rapid US, normal Uganda, and rapid Uganda
scenarios and medium revenue stream. Total discounted
revenue for the medium revenue assumption was $28.0
million at normal development and $46.6 million at
rapid development. Net present values ranged between
$6.8 million and $162.1 million for the 12 combinations
of costs and revenues modeled.
CONCLUSIONS: Drugs for tuberculosis will have a pos-
itive return on investment if molecules can be identified
when they enter Phase 1 of development.
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OBJECTIVES: To assess the compliance with antibiotic
prophylaxis practices and identify the factors associated
with practice variations in total hip replacement (THR)
surgery.
METHODS: We carried out a retrospective survey of
medical records in the orthopedic surgery department in
a 2,200-bed university hospital. A sample of 416 patients
undergoing THR from January 1999 to December 2000
was drawn. Practice conformity was evaluated based on
French guidelines for good clinical practice concerning
antibiotic prophylaxis in orthopedic surgery. Five major
criteria were used: antibiotic prophylaxis use; choice of
molecule; dosage at first injection; time between first in-
jection and incision; total duration. A multilevel hierar-
chical logistic regression analysis was performed using
global conformity as the dependant variable.
RESULTS: Among the 386 medical records analyzed, an-
tibiotic prophylaxis was used in 366 (95%) interventions.
The choice of molecule was consistent with the reference
for 258 (70%) patients. Among patients receiving a rec-
ommended molecule, dosage and timing of first injection
were consistent respectively for 98% (290/296) and 80%
